Fresh analysis indicates that people who discontinue new GLP-1 drugs like Wegovy and Mounjaro can put back on reduced body mass at a significantly accelerated pace than those who stop traditional lifestyle plans.
Findings released in a major medical journal demonstrates that while obese people can lose a large proportion of their total mass while using the jabs, the mass is regained at an average rate of 0.8 kg per month after stopping.
"Users purchasing these medications must be informed of the potential of quick rebound weight gain when the treatment concludes," cautioned expert Dr. Susan Jebb.
That rate of regain means a reversion to pre-treatment weight within about one and a half years.
Weighing Therapies
The analysis, which reviewed dozens of studies involving thousands of participants, compared the effects of these new drugs with older methods.
Researchers point out that people who shed pounds through dieting usually see a slower weight regain—around 0.1 kg a month—post-intervention.
The Reason for the Quick Rebound
Experts propose the way of the jabs accounts for the amplified rebound.
The injections copy a natural hormone called GLP-1, which controls hunger.
"Artificially providing the hormone concentrations far above than the body's typical production could lead to the system to generate a reduced amount of its own natural GLP-1, and could lessen sensitivity to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Stopping of this GLP-1 'fix' means hunger is uncontrolled, making binge eating far more likely."
A Lifelong Disease?
The NHS advise the injections for people with weight-linked health risks, accompanied by prescribed lifestyle changes.
Professionals argue that, considering the significant potential of relapse, the therapy might need to be ongoing.
This perspective is echoed by drug manufacturers, who say that the findings "highlight the persistent character of obesity," similar to managing conditions like high blood pressure.
User Accounts
Users who have come off the medication explain a powerful resurgence of appetite.
"It was like a switch that goes on and you become ravenous," said an individual.
This difficulty is worsened if individuals have not established sustainable lifestyle or habit modifications during therapy.
Widespread Use
Survey data indicate that a significant number of people in the UK have used these injections in the past year, with demand being substantial.
- Adoption is greater among females than men.
- The 40s and 50s age group shows the greatest level of interest.
- Many access the drugs through private healthcare rather than the NHS.
Finally, clinicians emphasize that while these medications are effective agents for weight loss, they are not a standalone fix and lasting health benefits likely depends on combined lifestyle management.
